175 related articles for article (PubMed ID: 32127473)
1. The atomistic level structure for the activated human κ-opioid receptor bound to the full Gi protein and the MP1104 agonist.
Mafi A; Kim SK; Goddard WA
Proc Natl Acad Sci U S A; 2020 Mar; 117(11):5836-5843. PubMed ID: 32127473
[TBL] [Abstract][Full Text] [Related]
2. Molecular switches of the κ opioid receptor triggered by 6'-GNTI and 5'-GNTI.
Cheng J; Sun X; Li W; Liu G; Tu Y; Tang Y
Sci Rep; 2016 Jan; 6():18913. PubMed ID: 26742690
[TBL] [Abstract][Full Text] [Related]
3. Structure of the µ-opioid receptor-G
Koehl A; Hu H; Maeda S; Zhang Y; Qu Q; Paggi JM; Latorraca NR; Hilger D; Dawson R; Matile H; Schertler GFX; Granier S; Weis WI; Dror RO; Manglik A; Skiniotis G; Kobilka BK
Nature; 2018 Jun; 558(7711):547-552. PubMed ID: 29899455
[TBL] [Abstract][Full Text] [Related]
4. Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor.
Che T; Majumdar S; Zaidi SA; Ondachi P; McCorvy JD; Wang S; Mosier PD; Uprety R; Vardy E; Krumm BE; Han GW; Lee MY; Pardon E; Steyaert J; Huang XP; Strachan RT; Tribo AR; Pasternak GW; Carroll FI; Stevens RC; Cherezov V; Katritch V; Wacker D; Roth BL
Cell; 2018 Jan; 172(1-2):55-67.e15. PubMed ID: 29307491
[TBL] [Abstract][Full Text] [Related]
5. The G protein-first activation mechanism of opioid receptors by Gi protein and agonists.
Mafi A; Kim SK; Goddard WA
QRB Discov; 2021; 2():e9. PubMed ID: 37529677
[TBL] [Abstract][Full Text] [Related]
6. An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.
French AR; van Rijn RM
Pharmacol Res; 2022 Mar; 177():106091. PubMed ID: 35101565
[TBL] [Abstract][Full Text] [Related]
7. Study of a structurally similar kappa opioid receptor agonist and antagonist pair by molecular dynamics simulations.
Kolinski M; Filipek S
J Mol Model; 2010 Oct; 16(10):1567-76. PubMed ID: 20195661
[TBL] [Abstract][Full Text] [Related]
8. Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site.
Uprety R; Che T; Zaidi SA; Grinnell SG; Varga BR; Faouzi A; Slocum ST; Allaoa A; Varadi A; Nelson M; Bernhard SM; Kulko E; Le Rouzic V; Eans SO; Simons CA; Hunkele A; Subrath J; Pan YX; Javitch JA; McLaughlin JP; Roth BL; Pasternak GW; Katritch V; Majumdar S
Elife; 2021 Feb; 10():. PubMed ID: 33555255
[TBL] [Abstract][Full Text] [Related]
9. Exploration of the SAR Connection between Morphinan- and Arylacetamide-Based κ Opioid Receptor (κOR) Agonists Using the Strategy of Bridging.
Liu X; Jiang S; Kong L; Ye R; Xiao L; Xu X; He Q; Wei Y; Li Z; Sun H; Xie Q; Xu X; Lu Y; Wang Y; Li W; Fu W; Qiu Z; Liu J; Shao L
ACS Chem Neurosci; 2021 Mar; 12(6):1018-1030. PubMed ID: 33650843
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor.
Mafi A; Kim SK; Goddard WA
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16346-16355. PubMed ID: 32601232
[TBL] [Abstract][Full Text] [Related]
11. The seventh transmembrane domains of the delta and kappa opioid receptors have different accessibility patterns and interhelical interactions.
Xu W; Campillo M; Pardo L; Kim de Riel J; Liu-Chen LY
Biochemistry; 2005 Dec; 44(49):16014-25. PubMed ID: 16331961
[TBL] [Abstract][Full Text] [Related]
12. Collybolide is a novel biased agonist of κ-opioid receptors with potent antipruritic activity.
Gupta A; Gomes I; Bobeck EN; Fakira AK; Massaro NP; Sharma I; Cavé A; Hamm HE; Parello J; Devi LA
Proc Natl Acad Sci U S A; 2016 May; 113(21):6041-6. PubMed ID: 27162327
[TBL] [Abstract][Full Text] [Related]
13. Molecular modeling of salsolinol, a full G
Berríos-Cárcamo P; Rivera-Meza M; Herrera-Marschitz M; Zapata-Torres G
Chem Biol Drug Des; 2019 Aug; 94(2):1467-1477. PubMed ID: 30920734
[TBL] [Abstract][Full Text] [Related]
14. Structural insights into µ-opioid receptor activation.
Huang W; Manglik A; Venkatakrishnan AJ; Laeremans T; Feinberg EN; Sanborn AL; Kato HE; Livingston KE; Thorsen TS; Kling RC; Granier S; Gmeiner P; Husbands SM; Traynor JR; Weis WI; Steyaert J; Dror RO; Kobilka BK
Nature; 2015 Aug; 524(7565):315-21. PubMed ID: 26245379
[TBL] [Abstract][Full Text] [Related]
15. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor.
Remmers AE; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
J Pharmacol Exp Ther; 1999 Feb; 288(2):827-33. PubMed ID: 9918595
[TBL] [Abstract][Full Text] [Related]
16. How Does Agonist and Antagonist Binding Lead to Different Conformational Ensemble Equilibria of the κ-Opioid Receptor: Insight from Long-Time Gaussian Accelerated Molecular Dynamics Simulation.
An X; Bai Q; Bing Z; Zhou S; Shi D; Liu H; Yao X
ACS Chem Neurosci; 2019 Mar; 10(3):1575-1584. PubMed ID: 30372027
[TBL] [Abstract][Full Text] [Related]
17. The structural basis of the dominant negative phenotype of the Gαi1β1γ2 G203A/A326S heterotrimer.
Liu P; Jia MZ; Zhou XE; De Waal PW; Dickson BM; Liu B; Hou L; Yin YT; Kang YY; Shi Y; Melcher K; Xu HE; Jiang Y
Acta Pharmacol Sin; 2016 Sep; 37(9):1259-72. PubMed ID: 27498775
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of conformational states, dynamics, and mechanism of binding in human κ-opioid receptor complexes.
Leonis G; Avramopoulos A; Salmas RE; Durdagi S; Yurtsever M; Papadopoulos MG
J Chem Inf Model; 2014 Aug; 54(8):2294-308. PubMed ID: 25060329
[TBL] [Abstract][Full Text] [Related]
19. Propagation of conformational changes during μ-opioid receptor activation.
Sounier R; Mas C; Steyaert J; Laeremans T; Manglik A; Huang W; Kobilka BK; Déméné H; Granier S
Nature; 2015 Aug; 524(7565):375-8. PubMed ID: 26245377
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of the Apo µ-Opioid Receptor in Complex with Gi Protein.
Lima MRP; Bezerra RFS; Serafim DDB; Sena Junior DM
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
